BEST AVAILABLE COPY

Figure 1
Biopolymer Indicative of Disease State - MW 1211

Sequence	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f
MW	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211
Disease	Mi	MI ·	MI	MI	Mi	MI	M	, IW	M	IW	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	CHF	C汗	봈	CAF	CHF	CHF	CHF	덌	CHF	CHF	CHF	CHF	CHF								
Patient History		GE (gastroesophageal) reflux	Inferior MI, Hiatal Hernia	MI, NIDDM							Acute CVA, Basal ganglia	HTN, previous CVA, CVA (R MCA) used tP	CVA, transfer to VA	HTN, ICH	CVA,	HTN, acute CVA (R subcortical_	HTN, Diabetes, acute CVA (R parietal)	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	\ STAGE 3	STAGE 3	STAGE 3
Age	7.7	65	20	65	58	52	65				54	72	47	56	72	72	- 67	61	65	67	75	77	65	67	67	79	9	43	45	59	99	51	64	59	76	51	62	70
Gender	IL.	Σ	L	ш	M	M	Σ				ı	Σ	Σ	Σ	Σ	Σ	F	Σ	L	ш	ட	ட	L	Σ	Σ	Σ	Σ	Σ	Σ	Σ	ш.	Σ	Σ	Σ	IL.	Σ	Σ	Σ
Code #	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	HNS-SJ33	CU-15	CU-18	CU-19	CU-30	CU-33	CU-37	CU-38	23604 - KKB	23707 - KL	22703 - MM	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB

The fact that the first that the first than the fact that the fact that

SJ CON 10 2000 2000 SPECTRA SHOWING DISEASE INDICATIVE MARKER 1800 1800 FIGURE 2 1600 1600 1400 1400 Complement C3f - 1211 Da (H)RIHWESASLL 20

SPECTRA SHOWING DISEASE INDICATIVE MARKER

FIGURE 2 Complement C3f - 1211 (H)RIHWESASLL[R]